Article
p73 as a Pharmaceutical Target for Cancer Therapy
1 Feb 2011
Abstract excerpt
About half of all human tumors contain an inactivating mutation of p53, while in the remaining tumors, the p53 pathway is frequently abrogated by alterations of other components of its signaling pathway. In humans, the p53 tumor suppressor is part of a small gene family that includes two other members, p73 and p63, structurally and functionally related to p53. Accumulating evidences indicate that all p53-family...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
